Ernexa Therapeutics (NASDAQ:ERNA) Issues Quarterly Earnings Results, Beats Estimates By $1.95 EPS

Ernexa Therapeutics (NASDAQ:ERNA) issued its quarterly earnings data on Friday. The company reported ($1.89) EPS for the quarter, topping the consensus estimate of ($3.84) by $1.95, Zacks reports.

Ernexa Therapeutics Stock Performance

Shares of NASDAQ ERNA traded up $0.04 during trading hours on Friday, reaching $1.87. 7,904 shares of the stock traded hands, compared to its average volume of 63,210. Ernexa Therapeutics has a 52-week low of $1.74 and a 52-week high of $46.11. The company’s 50-day simple moving average is $3.01 and its two-hundred day simple moving average is $6.91.

Analyst Upgrades and Downgrades

ERNA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.